Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515549 | 1.00 | GPR3 (0.39) | GPR3 | |
| SCHEMBL14778869 | 1.00 | GPR3 (0.39) | GPR3 | |
| SCHEMBL17440954 | 0.84 | GPR3 (0.35) | GPR3 | |
| SCHEMBL16700406 | 0.84 | GPR3 (0.35) | GPR3 | |
| SCHEMBL17440952 | 0.84 | GPR3 (0.35) | GPR3 | |
| SCHEMBL16708945 | 0.84 | GPR3 (0.35) | GPR3 | |
| SCHEMBL16700407 | 0.84 | GPR3 (0.35) | GPR3 | |
| SCHEMBL15774056 | 0.83 | — | — | |
| SCHEMBL20880442 | 0.81 | GPR3 (0.33) | GPR3 | |
| SCHEMBL18717568 | 0.81 | GPR3 (0.33) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025038927-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-3434674-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162133-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | 上海海和药物研究开发有限公司 | 2017-09-28 | — | — | WO | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | GPR3 4463/4885 |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | GPR3 4463/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | GPR3 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.